CKChristian Kuhn

Christian Kuhn

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Christian Kuhn has a total of 62 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Risk of Venous Thromboembolism in Kidney Transplant Recipients with Autosomal Dominant Polycystic Kidney Disease

    by Thomas Bais, Ahmad A. Alnaim, Erzsi Tegzess, Isabelle Binet, Michael Dickenmann, Dela Golshayan, Fadi Haidar, Christian Kuhn, Thomas Schachtner, Kerstin Hübel, et al.

    Background: Kidney transplant recipients with autosomal dominant polycystic kidney disease (ADPKD) may be at higher risk of venous thromboembolism than non-ADPKD recipients. Methods: We conducted an observational study of adult kidney transplant recipients at a single center, the University Medical Center Groningen (UMCG; n=1179, 393 with ADPKD), and replicated key analyses in the multicenter Swiss Transplant Cohort Study (STCS; n=4415, 710 with ADPKD). The primary endpoint was time to first venous thromboembolism after transplantation or death related to venous thromboembolism (identified through medical record review), analyzed using Kaplan–Meier estimates and Cox regression. Data were pooled for subgroup analyses and to assess determinants of post-transplant venous thromboembolism risk. Results: Venous thromboembolism occurred more often in ADPKD than non-ADPKD kidney transplant recipients (log-rank p=0.04 and p<0.001 for UMCG and STCS, respectively). The 10-year cumulative venous thromboembolism incidence was 13.5% [95% CI: 9.4, 17.5], versus 9.6% [95% CI: 7.0, 12.1] in ADPKD versus non-ADPKD recipients in UMCG, and 21.0% [95% CI: 17.0, 24.7] versus 15.1% [95% CI: 13.5, 16.6] in STCS. Median [Q1, Q3] time to venous thromboembolism were similar across cohorts (UMCG: 1.7 [0.4, 4.9], STCS: 1.4 [0.2, 4.8] years). Venous thromboembolism risk was highest in the early (<2 years) post-transplant period. After adjustment for venous thromboembolism risk factors, ADPKD remained independently associated with post-transplant venous thromboembolism in both cohorts (UMCG HR 1.80 [95% CI: 1.21, 2.69]; STCS HR 1.39 [95% CI: 1.13, 1.72]). The association between ADPKD and risk of venous thromboembolism was more pronounced in males. Hemoglobin levels after kidney transplantation were approximately 7.0 ± 0.8% higher in ADPKD recipients, particularly in males, with corresponding higher risks of erythrocytosis during follow-up. Incorporating longitudinal hemoglobin as a time-varying covariate attenuated the association between ADPKD and venous thromboembolism, suggesting that the association was at least partially driven by higher hemoglobin levels. Conclusions: Kidney transplant recipients were at high risk for venous thromboembolism, and those with ADPKD are at an even higher risk.

  • Open Access

    Single-kidney transplantation with discarded partner kidney vs. Dual kidney transplantation: results from a national cohort study

    by Stephanie Näf, Simon Schwab, Isabelle Binet, Alexander Ritter, Max J Rieger, Déla Golshayan, Fadi Haidar, Franz Immer, Thomas Schachtner, Stefan Schaub, et al.

    The transplantation of a single kidney, while its partner kidney is discarded despite both having been initially offered (dual-offered, single-transplanted

  • [Persistent electrolyte deficiency in an oncology patient].

    by Nicole Maurer, Katrin Ledergerber, Barbara Denecke, Christian Kuhn

    We report the case of a 47-year-old patient with a dedifferentiated mediastinal-thoracic liposarcoma who developed electrolyte disturbances during chemotherapy with Ifosfamide and Doxorubicin. Initially, a refeeding syndrome was suspected, supported by hypokalemia, hypomagnesemia, and hypophosphatemia. However, the prolonged course of electrolyte abnormalities, along with the presence of normoglycemic glucosuria and proteinuria, were not consistent with this diagnosis. Over time, a partial Fanconi syndrome was confirmed, reflecting a proximal tubular dysfunction - a well-known complication of Ifosfamide therapy. Notably, standard markers of kidney function, such as eGFR, remained within normal limits early in the course, highlighting the importance of sensitive early indicators like electrolyte abnormalities and glucosuria. Early urine diagnostics (ideally prior to the initiation of electrolyte replacement) are essential for recognizing and classifying this potentially serious adverse effect.

  • Why Living Kidney Donors Are Declined: A Swiss Single Center Observation Over 15 Years

    by Christian Kuhn, Aurelia Schnyder, Wolfgang Ender, Anna Wiegand, Patrick Folie, Isabelle Binet, Alexander Ritter

  • [Eye Spy: What Red Eyes Could Reveal About Your Kidneys].

    by Pascal Gantenbein, Isabelle Binet, Regula Laux, Sascha Mathias Jung, Annette Enzler-Tschudy, Christian Kuhn

    TINU syndrome (Tubulointerstitial Nephritis and Uveitis) is a rare autoimmune disorder that causes inflammation in the kidneys and eyes. It manifests as uveitis and impaired kidney function. Diagnosis is based on symptom correlation and kidney biopsy. Differential diagnoses include infectious and immunological conditions. Treatment primarily involves systemic corticosteroids and topical steroids for uveitis. Relapses may occur, especially in adults, while the prognosis in children tends to be more favorable.

  • Open Access

    The effects of lymphocele formation after living donor kidney transplantation on mid-term allograft function

    by Christian Kuhn, Bernd Jänigen, Laura Matuschik, Max J. Rieger, Daniel Sidler, Stefan Zschiedrich

    Despite advances in kidney transplant surgery and immunosuppression, lymphoceles remain a frequent complication in the early postoperative period following kidney transplantation, often requiring reintervention. While long-term outcomes such as patient and allograft survival are well studied, the impact of lymphocele formation on mid-term allograft function remains unclear. This multicentric study included 711 recipients of living donor kidney transplants to investigate the impact of lymphocele formation on mid-term graft function. Outcomes assessed included estimated glomerular filtration rate (eGFR) at 12 months, eGFR slope, and both patient and allograft survival. Lymphoceles were detected in 17.4% of the recipients, with a median volume of 129 ml, and 71.8% of these patients required intervention. Patients without lymphocele formation had a significantly higher median eGFR at 12 months (52.1 ml/min/1.73 m²) compared to those with lymphoceles (48.7 ml/min/1.73 m²). Additionally, patients with lymphocele formation demonstrated a steeper median eGFR slope (-2.3 ml/min/1.73 m²/year) than those without (-0.3 ml/min/1.73 m²/year). No significant difference was observed in the composite outcome of allograft survival and patient death between the two groups. Lymphocele formation after living donor kidney transplantation is associated with a steeper decline in graft function. They may reflect a disturbed microvasculature and warrant closer control of cardiovascular risk factors and allograft monitoring of affected patients. Not applicable, the study is not a clinical trial.


  • Open Access

    EXAM: Ex-vivo allograft monitoring dashboard for the analysis of hypothermic machine perfusion data in deceased-donor kidney transplantation

    by Simon Schwab, Hélène Steck, Isabelle Binet, Andreas Elmer, Wolfgang Ender, Nicola Franscini, Fadi Haidar, Christian Kuhn, Daniel Sidler, Federico Storni, et al.

    Deceased-donor kidney allografts are exposed to ischemic injury during ex vivo transport due to the lack of blood oxygen supply. Hypothermic machine perfusion (HMP) effectively reduces the risk of delayed graft function in kidney transplant recipients compared to standard cold storage. However, no free software implementation is available to analyze HMP data for state-of-the-art visualization and quality control. We developed the tool EXAM (ex-vivo allograft monitoring) as an interactive analytics dashboard. We wrote functions in the R programming language to read, process, and analyze HMP data from the LifePort kidney transporter (Organ Recovery Systems, USA). Time series for pressure, flow rate, organ resistance, and temperature are visualized, and relevant statistical indicators have been developed. We explain how data were processed, and indicators were calculated, and we present summary statistics for N = 255 kidney allografts receiving machine perfusion in Switzerland between 2020 and 2023. Median (interdecile range, IDR) of the main indicators were as follows: perfusion duration 5.18 hours (2.29−11.2), flow rate 110 ml/min (52.9−167), ice temperature 1.97°C (1.53−3.07), and perfusate temperature 6.68°C (5.58−8.36). We implemented the dashboard to identify issues, such as atypical perfusion parameters, high ice, or high perfusate temperature to inform transplant centers for quality assurance. In conclusion, EXAM is a free tool that statisticians and data scientists can quickly deploy to enable quality control at transplant organizations that use LifePort kidney transporters. An online viewer is available at https://data.swisstransplant.org/exam/.


  • Open Access

    Was ist gesichert in der Therapie der metabolischen Azidose bei chronischer Nierenkrankheit?

    by Alexander Ritter, Christian Kuhn, Nilufar Mohebbi

    Zusammenfassung: Eine präzise Regulation des Säure-Basen-Haushalts ist für viele Organe und physiologische Prozesse essenziell. Säureretention und metabolische Azidose (MA) sind häufige Komplikationen bei chronischer Nierenkrankheit („chronic kidney disease“ [CKD]) und treten auch nach Nierentransplantation auf. Neben diätetischen Maßnahmen kommen medikamentöse Therapien zur Azidosekorrektur zum Einsatz, mit Natrium(hydrogen)karbonat als am häufigsten eingesetzter Substanz. Mehrere Studien konnten einen positiven Effekt einer Azidosekorrektur auf die CKD-Progression aufzeigen. Die Studienresultate sind jedoch nicht einheitlich und es ist von eher kleineren Behandlungseffekten auszugehen. Nach Nierentransplantation konnte bisher keine positive Wirkung auf die Transplantatfunktion nachgewiesen werden. Die MA ist mit einer eingeschränkten Knochenqualität assoziiert, wobei Alkaliinterventionsstudien bislang einen positiven Effekt auf Marker des Knochenstoffwechsels, nicht jedoch auf die Knochendichte gezeigt haben. Die MA ist mit einer erhöhten kardiovaskulären Ereignisrate assoziiert, Interventionsstudien mit harten kardiovaskulären Endpunkten fehlen jedoch bis dato. Eine Interventionsstudie mit jedoch wesentlichen Limitationen konnte einen positiven Effekt einer Alkalitherapie auf die Mortalität zeigen. Eine Azidosekorrektur scheint sich positiv auf den Protein- und Muskelkatabolismus auszuwirken, wobei eine Verbesserung der körperlichen Leistungsfähigkeit in einer geriatrischen Population nicht gezeigt werden konnte. Bezüglich der endokrinologischen Effekte einer Alkalitherapie existieren nur sehr wenige Studien. Hier zeigten sich ein günstiger Effekt auf den Glukosestoffwechsel und ein möglicher Nutzen in Bezug auf die Schilddrüsenfunktion bei prädialytischen Patienten mit CKD. Aufgrund der insgesamt eher geringen bis moderaten Evidenz für den Nutzen einer Alkalitherapie sowie angesichts der teilweise widersprüchlichen Studienlage wird in den aktualisierten Leitlinien von Kidney Disease: Improving Global Outcomes (KDIGO) die Empfehlung für Erwachsene abgeschwächt und eine Alkalibehandlung vorgeschlagen, um ein Serumbikarbonat < 18 mmol/l (bislang < 22 mmol/l) und die damit verbundenen Komplikationen zu vermeiden.

  • Open Access

    Metabolic acidosis in chronic kidney disease: mere consequence or also culprit?

    by Christian Kuhn, Nilufar Mohebbi, Alexander Ritter

    Metabolic acidosis is a frequent complication in non-transplant chronic kidney disease (CKD) and after kidney transplantation. It occurs when net endogenous acid production exceeds net acid excretion. While nephron loss with reduced ammoniagenesis is the main cause of acid retention in non-transplant CKD patients, additional pathophysiological mechanisms are likely inflicted in kidney transplant recipients. Functional tubular damage by calcineurin inhibitors seems to play a key role causing renal tubular acidosis. Notably, experimental and clinical studies over the past decades have provided evidence that metabolic acidosis may not only be a consequence of CKD but also a driver of disease. In metabolic acidosis, activation of hormonal systems and the complement system resulting in fibrosis have been described. Further studies of changes in renal metabolism will likely contribute to a deeper understanding of the pathophysiology of metabolic acidosis in CKD. While alkali supplementation in case of reduced serum bicarbonate < 22 mmol/l has been endorsed by CKD guidelines for many years to slow renal functional decline, among other considerations, beneficial effects and thresholds for treatment have lately been under intense debate. This review article discusses this topic in light of the most recent results of trials assessing the efficacy of dietary and pharmacological interventions in CKD and kidney transplant patients.


  • Relevance of deceased donor proteinuria for kidney transplantation: A comprehensive national cohort study

    by Christian Kuhn, Alex Born, Andrea Karolin, Brian Lang, Isabelle Binet, Délaviz Golshayan, Fadi Haidar, Thomas F. Müller, Stefan Schaub, Franz Immer, et al.

    Purpose: Proteinuria is frequent in patients with nephropathies and associated with progressive kidney disease and risk for end stage kidney disease. However, the relevance of deceased donor proteinuria on transplant outcome remains uncertain. In this nationwide cohort study, we evaluated the prevalence of proteinuria in deceased donor candidates and measured the impact on outcome after kidney transplantation.Methods: Data from the Swiss Organ Allocation System and the Swiss Transplant Cohort Study were analyzed, comprising 1725 donors and 1516 recipients transplanted between 2008 and 2019. We correlated urine findings with donor characteristics and quantified the impact of proteinuria on allograft function at 12 months and survival.Results: Proteinuria influenced allocation decisions in 4.5% of nonimmunological organ declines and was the leading cause for decline in 0.2% of cases. 74.1%, 51.4%, and 35.3% of donor candidates had a baseline proteinuria above 15, 30, and 50 mg protein/mmol urine creatinine, respectively. Proteinuria above 30 mg/mmol was associated with female donor sex, mechanical resuscitation, acute kidney injury, and time delay between ICU entry and urine sampling. Donor proteinuria was not associated with patient or allograft survival, nor allograft function at 12 months.Conclusion: We report a high prevalence of proteinuria in donor candidates, without evidence of a deleterious impact of proteinuria on graft function and/or survival. Therefore, low‐level proteinuria should not be considered a limiting contraindication for kidney allocation in deceased donor transplant.